SECRETORY IGA

Secretory IgA, Inc. is an early stage drug discovery and development company. The mission of this company is to develop orally available antibody agents for the treatment of intestinal diseases... Secretory IgA, Inc.'s initial product is secretory immunoglobulin A (IgA). This biological therapeutic will treat Clostridioide difficile-associated disease, an intestinal disease which occurs when the intestinal bacteria are disturbed by antibiotic treatment and is caused by Clostridioide difficile bacterial toxins. Clostridioides difficile associated disease can cause diarrhea, severe cramps and high fever. This condition may result in severe outcomes, such as surgical removal of the colon and death, especially in elderly patients and patients with compromised immune systems. Successful proof of principle experiments have been performed (https://doi.org/10.1093/infdis/jiab087). Other intestinal conditions which are expected to respond to treatment with secretory IgA include other bacteria..

Also known as: Secretory IgA, Inc.

Primary location: Ann Arbor United States